Efficacy of bi-weekly docetaxel in hormone-sensitive metastatic prostate cancer (mHSPC).

被引：0
|
作者：
Lombana Quinonez, Milton Alberto
Milena Torres, Ana
Gonzalez, Guido
机构：
[1] Ctr Integral Canc Clin Occidente, Cali, Colombia
[2] Nalt Med Solut, Cali, Colombia
[3] Clin Occidente, Cali, Colombia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17070
引用
收藏
页数：1
相关论文
共 50 条
  • [21] An adjusted indirect treatment comparison (ITC) of enzalutamide (ENZ) versus docetaxel (DOC) for metastatic hormone-sensitive prostate cancer (mHSPC)
    Ohlmann, Carsten
    Armstrong, Andrew
    Gratzke, Christian
    Sugg, Jennifer
    Ganguli, Arijit
    Dornstauder, Eugen
    Gross-Langenhoff, Marco
    Brauner, Reinhard
    Stenzl, Arnulf
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 109 - 109
  • [22] Metastatic hormone-sensitive prostate cancer
    Gravis, Gwenaelle
    Salem, Naji
    Walz, Jochen
    BULLETIN DU CANCER, 2015, 102 (01) : 57 - 64
  • [23] Feasibility of cotargeting cell cycle and androgen signaling in metastatic hormone-sensitive prostate cancer (mHSPC).
    Palmbos, Phillip Lee
    Tomlins, Scott A.
    Agarwal, Neeraj
    Twardowski, Przemyslaw
    Morgans, Alicia Katherine
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [24] ARASENS: A phase 3 trial of darolutamide in males with metastatic hormone-sensitive prostate cancer (mHSPC)
    Tombal, B.
    Saad, F.
    Hussain, M.
    Sternberg, C. N.
    Fizazi, K.
    Crawford, E. D.
    Yamada, K.
    Kappeler, C.
    Kuss, I.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)
    Parnis, F.
    Tombal, B.
    Hussain, M.
    Saad, F.
    Fizazi, K.
    Sternberg, C. N.
    Crawford, E. D.
    Kopyltsov, E.
    Kalebasty, A. Rezazadeh
    Alekseev, B. Y.
    Montesa Pino, A.
    Ye, D.
    Melo Cruz, F. J. S.
    Tammela, T.
    Suzuki, H.
    Joensuu, H.
    Thiele, S.
    Li, R.
    Kuss, I.
    Smith, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S1501 - S1502
  • [26] Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer
    Lage, Daniel E.
    Michaelson, Dror M.
    Lee, Richard J.
    Greer, Joseph A.
    Temel, Jennifer S.
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [27] Early docetaxel-resistance in metastatic hormone-sensitive prostate cancer.
    Bukhari, Nedal
    Potvin, Kvica R.
    Ernst, D. Scott
    Sax, Lori
    Winquist, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [28] Is Docetaxel Chemotherapy a New Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer?
    Liaw, Bobby C.
    Oh, William K.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2015, 11 (09) : 17 - 20
  • [29] Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
    Talwar, Harkirat Singh
    INDIAN JOURNAL OF UROLOGY, 2021, 37 (03) : 288 - 290
  • [30] Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer
    Daniel E. Lage
    M. Dror Michaelson
    Richard J. Lee
    Joseph A. Greer
    Jennifer S. Temel
    Christopher J. Sweeney
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 1181 - 1188
12345